RESTRUCTURING

On an ongoing basis, we review the global economy, the healthcare industry, and the markets in which we compete to identify opportunities for efficiencies, enhance commercial capabilities, align our resources and offer our customers better solutions. In order to realize these opportunities, we undertake restructuring-type activities to transform our business.

During the first quarter of fiscal 2017, in connection with our global strategic review, we launched a restructuring program designed to reposition our organization and improve our cost structure. This program includes both a reduction of headcount and operating costs as well as projects to simplify product lines. We may also take steps to modify our manufacturing operations to align with our strategic direction.

We expect to incur approximately $26 million of restructuring and turnaround related costs, comprised of $17 million in termination benefits and $9 million in other related exit costs. Substantially all of these charges result in cash outlays expected to be incurred during fiscal 2017. Savings from this program are estimated to be approximately $40 million in fiscal 2017. The Company is evaluating non-performing assets and business units as part of its turnaround, which may result in future cash outlays or non-cash charges. During the three and six months ended October 1, 2016, we incurred $1.1 million and $18.8 million, respectively, of restructuring and turnaround charges under this program. Additionally, during the three and six months ended October 1, 2016, we recorded $0.5 million and $1.6 million, respectively, of restructuring and turnaround charges under a prior program.

The following summarizes the restructuring activity for the six months ended October 1, 2016:



(In thousands)	Severance and Other Employee Costs			Other Costs			Asset Write Down			Total Restructuring
Balance at April 2, 2016	$	8,752		$	—		$	—		$	8,752
Costs incurred, net of reversals	15,192			506			334			16,032
Payments	(12,645		)	(393		)	—			(13,038		)
Non-cash adjustments	—						(334		)	(334		)
Balance at October 1, 2016	$	11,299		$	113		$	—		$	11,412

Substantially all of the restructuring expenses have been included as a component of selling, general and administrative expenses in the accompanying consolidated statements of income. As of October 1, 2016, we had a restructuring liability of $11.4 million, of which approximately $10.8 million is payable within the next twelve months.

In addition to the restructuring expenses included in the table above, during the six months ended October 1, 2016, we also incurred $4.4 million of costs that do not constitute as restructuring under ASC 420, which we refer to as turnaround costs. These costs consist primarily of expenditures directly related to our restructuring initiative and include program management, implementation of the global strategic review initiatives and accelerated depreciation.

The tables below present restructuring and turnaround costs by reportable segment:



Restructuring costs	Three Months Ended						Six Months Ended
(in thousands)	October 1, 2016			September 26, 2015			October 1, 2016		September 26, 2015
Japan	$	(38	)	$	—		$	836	$	9
EMEA	(63		)	98			3,011		118
North America Plasma	(7		)	—			368		—
All Other	(246		)	4,826			11,817		14,256
Total	$	(354	)	$	4,924		$	16,032	$	14,383

Turnaround costs	Three Months Ended						Six Months Ended
(in thousands)	October 1, 2016			September 26, 2015			October 1, 2016		September 26, 2015
Japan	$	1		$	47		$	2	$	191
EMEA	55			178			81		420
North America Plasma	936			(40		)	936		—
All Other	959			1,543			3,362		6,474
Total	$	1,951		$	1,728		$	4,381	$	7,085

Total restructuring and turnaround costs	$	1,597		$	6,652		$	20,413	$	21,468